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The push to develop commercially
viable cloned animals as a source
of organs for human transplants
ratcheted up another success last
month, but veteran Dolly, the
cloned sheep has raised some
doubts about the wider issues of
cloning.
Two teams produced piglets
cloned from adult cells in which a
copy of a gene controlling
production of a particular cell-
surface sugar had been knocked
out. Shortly before publication in
Science of details about one
group of piglets produced in the
autumn by a team at the
University of Missouri in
collaboration with scientists at
Immerge BioTherapeutics in
Charlestown, Massachusetts, PPL
Therapeutics, based near
Edinburgh, announced to the
media the birth of its knock-out
piglets on Christmas Day. Humans
do not produce this sugar which
leads to rapid rejection if organs
containing it are transplanted into
humans.
Pigs are the most promising
species for organ transplants
because they are physiologically
quite similar to humans. But
progress has been slow because
of fears new viruses may be
transmitted from pigs to humans
in a transplanted organ, and 
the rapid rejection of any pig
organ.
Earlier work has produced
transgenic pigs that produce
proteins that can protect the
organs from some immune attack.
But the latest work involved
knocking out the gene for
galactosyl-transferase needed to
make the sugar. The new cloned
piglets have one copy of the gene
disrupted but can still make the
sugar with the other copy of the
gene. Conventional breeding is
likely to used to create a double
knock-out that should not
produce any of the sugar and so
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Last month’s announcement of the birth of piglets lacking a gene
crucial in the acute rejection of organs for human transplant created
much excitement in both the media and markets but Dolly, the veteran
cloned sheep, cast a cloud of uncertainty over the new advances.
Nigel Williams reports.
Dolly dampener: the famous cloned sheep. seen here with the
head of the team that created her, Ian Wilmut of the Roslin Insti-
tute near Edinburgh, has cast doubt on new progress in the
cloning of transgenic pigs for potential sources of organs for
transplant into humans as there may be other factors in cloning
not yet known about. Photo: Science Photo Library
may be more suitable for
transplant to humans.
Amid acrimony about the
importance of peer review in
announcing such results — huge
media interest ensued and stock
value in the companies soared.
News was carried on the front
page of the Wall Street Journal
and in many British newspapers.
PPL denies it attempted to scoop
its competitors. It said it had
made a deliberate decision to
announce breakthroughs directly
to the press and stock markets in
1997, after it was criticised by the
financial community for waiting
seven months to reveal the
existence of Dolly in Nature. She
was created in collaboration with
scientists at the Roslin Institute, a
public sector establishment.
But things came quickly back
closer to earth with the
announcement that Dolly had
developed arthritis, which is
highly unusual in a sheep of her
age.
With sheep life expectancy
somewhere between 10 and 15,
Dolly is no spring lamb. But the
realisation that she suffers from
arthritis casts fresh doubts over
the entire controversial field of
cloning and spurs the anti-cloning
lobby to a new round of concerns.
The head of the original cloning
team, Ian Wilmut, at the Roslin
institute near Edinburgh, put a
brave face on the sheep’s
condition.
He said he was concerned and
called for more research into the
implications of cloning. But he
insisted that the technology was
crucial for medical science and
denied that he had opened a
Pandora’s box by showing that
animals can be cloned.
“This is an inefficient procedure.
We were always aware that there
was a risk that we would find
things like this. We were very
disappointed and very concerned
for the animals,” he said.
“We will never know in the case
of Dolly whether the condition is
because she is cloned or whether
it is an unfortunate accident that
she developed arthritis. What’s
very important is that not only we
at the institute, but others who
produce cloned animals should
monitor their health throughout
their entire life span.”
Vets at the institute have put
her on anti-inflammatory drugs
and prescribed a weight-loss and
exercise programme.
“Arthritis is not unknown in this
age of sheep,” says Dolly’s vet,
Tim King. “The strange thing
about Dolly is that arthritis
normally affects the elbow in
sheep. In Dolly her hip and knee
joints are affected.”
Animal cloning is already known
as an unreliable and risky
procedure. It took 276
unsuccessful attempts before
Dolly was produced. Many cloned
animals which are carried to term
die shortly after birth and suffer
deformities. The University of
Missouri team implanted 3,000
embryos in 28 surrogate sows to
get seven piglets born last
autumn. 
Some scientists believe the
problem is their inability to
reproduce the process of
‘imprinting’.
Even though the few clones
which make it to adulthood, such
as Dolly, may have seemed
healthy, there have already been
signs that at the cellular level, they
were ‘pre-aged’ from birth. The
ewe from whose cells Dolly was
cloned was six years old, so some
have argued that she is, in some
sense, eleven.
Wilmut said the development of
arthritis in Dolly was only one
minor new doubt to add to the
pile. “I don’t regard this as a major
setback,” he said. 
However, considerable hurdles
and doubts remain before
transplants may be possible. In
the UK any proposal would have
to get the approval of the
Xenotransplantation Interim
Authority, chaired by Lord
Habgood, former bishop of York.
And any application is likely to be
some years away, a spokesperson
for the Department of Health said.
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